Paxlovid or Remdesivir for Long-term Heart Issues After COVID-19
Antiviral Strategies in the Prevention of Long-term Cardiovascular Outcomes Following COVID-19: The paxloviD/Remdesivir Effectiveness For the prEvention of loNg coviD Clinical Trial
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 118 (estimated)
- Sponsor
- Mount Sinai Hospital, Canada · Other
This trial is looking for adults hospitalized with COVID-19 to see if Paxlovid or Remdesivir can prevent heart issues after recovery. Participants will need to provide consent and meet certain health criteria to join.
You may be able to join if
- I am at least 18 years old
- I tested positive for COVID-19 within 5 days of hospital admission
- I am not receiving supplemental oxygen
- I can provide written consent or have someone to help me do so
You may not be able to join if
- I have a severe allergy to Paxlovid or Remdesivir
- I have taken Paxlovid or Remdesivir in the last 14 days
- I am receiving supplemental oxygen
- I tested positive for COVID-19 in the past 5 to 90 days
- I have a life expectancy of 3 months or less
- I am pregnant or breastfeeding
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityThe DEFEND trial will be the world's first clinical trial to study the effectiveness of Paxlovid or Veklury in the prevention of cardiovascular post-acute sequelae of SARS-CoV-2 among hospitalized adults. Additionally, this pilot study will inform the design and conduct of a future full-scale multi-centre trial by testing the feasibility and accuracy of this study design.
Loading trial locations…